Revenue Recognition

9 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Revenue Recognition

4. Revenue Recognition

Overview

Revenue from contracts with customers is recognized in an amount that reflects the consideration we expect to receive in exchange for products when obligations under such contracts are satisfied. Revenue is generally recognized at a point-in-time when products are shipped, and control has passed to the customer. Such contracts can include various combinations of products that are generally accounted for as distinct performance obligations. Revenue is reduced in the period of sale for fees paid to distributors, which are inseparable from the distributor’s purchase of our product and for which we receive no goods or services in return. Revenue for the Diagnostics segment is reduced at the date of sale for product price adjustments payable to certain distributors under local contracts.

Revenue Disaggregation

The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics segment only):

Revenue by Reportable Segment & Geographic Region

	Three Months Ended June 30,							Nine Months Ended June 30,
	2021		2020		Inc (Dec)			2021		2020		Inc (Dec)
Diagnostics-
Americas	$	24,543	$	17,575		40	%	$	73,367	$	72,980		1	%
EMEA		6,251		3,576		75	%		18,352		16,853		9	%
ROW		395		447		(12	)%		1,740		1,498		16	%
Total Diagnostics		31,189		21,598		44	%		93,459		91,331		2	%
Life Science-
Americas		7,419		22,007		(66	)%		39,661		30,638		29	%
EMEA		15,723		26,227		(40	)%		70,084		41,305		70	%
ROW		9,180		14,965		(39	)%		38,488		26,240		47	%
Total Life Science		32,322		63,199		(49	)%		148,233		98,183		51	%
Consolidated	$	63,511	$	84,797		(25	)%	$	241,692	$	189,514		28	%

Revenue by Product Platform/Type

	Three Months Ended June 30,							Nine Months Ended June 30,
	2021		2020		Inc (Dec)			2021		2020		Inc (Dec)
Diagnostics-
Molecular assays	$	4,383	$	3,182		38	%	$	13,368	$	17,259		(23	)%
Non-molecular assays		26,806		18,416		46	%		80,091		74,072		8	%
Total Diagnostics	$	31,189	$	21,598		44	%	$	93,459	$	91,331		2	%
Life Science-
Molecular reagents	$	20,385	$	38,791		(47	)%	$	104,016	$	55,703		87	%
Immunological reagents		11,937		24,408		(51	)%		44,217		42,480		4	%
Total Life Science	$	32,322	$	63,199		(49	)%	$	148,233	$	98,183		51	%

Revenue by Disease State (Diagnostics segment only)

	Three Months Ended June 30,							Nine Months Ended June 30,
	2021		2020		Inc (Dec)			2021		2020		Inc (Dec)
Diagnostics-
Gastrointestinal assays	$	17,844	$	9,584		86	%	$	48,962	$	39,644		24	%
Respiratory illness assays		3,742		5,052		(26	)%		12,233		23,664		(48	)%
Blood chemistry assays		4,254		3,364		26	%		13,006		12,508		4	%
Other		5,349		3,598		49	%		19,258		15,515		24	%
Total Diagnostics	$	31,189	$	21,598		44	%	$	93,459	$	91,331		2	%

Royalty Income

Royalty income received from a third party related to sales of H. pylori products, totaled approximately $1,380 and $160 in the three months ended June 30, 2021 and 2020, respectively, and $5,085 and $2,365 in the nine months ended June 30, 2021 and 2020, respectively. Such revenue is included as part of Non-molecular assays and Other within the Revenue by Product Platform/Type and Revenue by Disease State tables, respectively, above.

Reagent Rental Arrangements

Revenue allocated to the lease elements of Reagent Rental arrangements totaled approximately $950 and $1,150 in the three months ended June 30, 2021 and 2020, respectively, and $2,730 and $3,400 in the nine months ended June 30, 2021 and 2020, respectively. Such revenue is included as part of net revenues in our Condensed Consolidated Statements of Operations.